Abstract：
:Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report five of 13 evaluable patients undergoing allogeneic sibling BM or PBSC transplantation for MM between 1990 and 1997 who met the criteria for adjuvant alpha-IFN therapy. A starting dose of 3 MU x 3/week was commenced at median time of day +126 (range day +112-224) post-transplant and was well-tolerated. In contrast to other reports we observed no increased toxicity in terms of GVHD compared to those patients not receiving alpha-IFN therapy and only one patient treated with alpha-IFN has developed chronic GVHD. Durable CRs were achieved in two patients within 8 weeks of starting therapy whilst two other patients required a longer course of alpha-IFN to achieve CR (36 weeks and 30 weeks, respectively). One patient whose paraprotein was rapidly rising at the time of alpha-IFN therapy clinically relapsed despite 6 months of treatment. None of the patients who achieved CR following alpha-IFN therapy have relapsed and we conclude that alpha-IFN is a safe and effective adjuvant treatment for some patients in the achievement of CR following allogeneic transplantation for myeloma.
journal_name
Bone Marrow Transplantjournal_title
Bone marrow transplantationauthors
Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NHdoi
10.1038/sj.bmt.1701403subject
Has Abstractpub_date
1998-10-01 00:00:00pages
639-43issue
7eissn
0268-3369issn
1476-5365journal_volume
22pub_type
杂志文章abstract：:We have evaluated the efficacy of administering recombinant human erythropoietin (rh-Epo) to 11 healthy bone marrow donors weighing less than 30 kg. Three weeks before harvesting, the donors received 100 units/kg/day rh-Epo subcutaneously and oral iron supplementation (2.5 mg/kg twice daily). Six children with hematoc...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1701310
更新日期：1998-07-01 00:00:00
abstract：:Pure red cell aplasia (PRCA) is characterized by a selective marrow aplasia of the erythroid compartment. Immunosuppressive therapy achieves good results in about 25% of cases, but relapses are frequent. Autologous or allogeneic haematopoietic stem cell transplantation (HSCT) may be valuable in selected patients. Here...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704419
更新日期：2004-04-01 00:00:00
abstract：:Hepatic venocclusive disease (VOD) is a common toxicity associated with myeloablative chemotherapy or chemoradiotherapy used to prepare patients for stem cell transplantation. A sizable proportion of patients who develop VOD die. It is clear that injury to endothelial cells and hepatocytes in zone 3 of the liver acinu...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/sj.bmt.1703014
更新日期：2001-06-01 00:00:00
abstract：:Serial liver biopsies were obtained in 20 patients undergoing bone marrow transplantation (BMT) for mucopolysaccharidosis (MPS). The 13 patients with MPS I, one with MPS II, four with MPS III, and two with MPS VI underwent liver biopsy prior to and from 1 to 37 months after BMT. The amount of accumulated glycosaminogl...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1992-09-01 00:00:00
abstract：:Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation. Pretransplant conditioning regimes cause release of proinflammatory cytokines that stimulate alloreactive donor T cells to attack recipient tissues. IL-10 has been shown to directly downregulate CD4+ T cells...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1705218
更新日期：2006-01-01 00:00:00
abstract：:We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2013.154
更新日期：2014-02-01 00:00:00
abstract：:We report a patient who developed early onset microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after allogeneic bone marrow transplantation (BMT). The clinical features and laboratory findings were not consistent with cyclosporin toxicity, graft-versus-host disease or cytomegalovirus infection as causativ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1995-05-01 00:00:00
abstract：:Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order t...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704711
更新日期：2005-01-01 00:00:00
abstract：:Syngeneic BMT was first performed successfully in China in 1964. In 1981, allogeneic BMT was applied in an acute leukemia patient with success. Since then, the number of BMTs has been increasing gradually, especially since the 1990s. More than 2000 stem cell transplants per year have been performed in recent years in ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2008.123
更新日期：2008-08-01 00:00:00
abstract：:A 20-year-old man with aplastic anemia developed myasthenia gravis (MG) 7 months after bone marrow transplantation (BMT) from an HLA one locus-mismatched sister. Proximal muscle weakness (predominant in the lower limbs) and dysphagia occurred without any other sign of graft-versus-host disease (GVHD), 1 month after ce...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1701297
更新日期：1998-07-01 00:00:00
abstract：:Hematopoietic progenitor cell levels were monitored in the peripheral blood of ten healthy adults receiving a single dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF). The objective was to determine the time and number of progenitor cells released into the peripheral blood, induced by a single ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1993-06-01 00:00:00
abstract：:Inadequate stem cell mobilization is seen in approximately 25% of patients undergoing autotransplantation for hematologic malignancies. Remobilization strategies include chemotherapy/cytokine combinations or high-dose cytokines alone or in combination. From 1/1997 to 7/2002, we remobilized 86 patients who failed an in...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1704486
更新日期：2004-05-01 00:00:00
abstract：:Patients who develop veno-occlusive disease (VOD) of the liver may have low plasma levels of the natural anticoagulants protein C and antithrombin III, but large vessel thromboses are not commonly reported in these patients. We reviewed the records of 1847 consecutive patients for evidence of portal vein thrombosis. E...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1703368
更新日期：2002-02-01 00:00:00
abstract：:Recombinant human (rHu) G-CSF has been widely used to treat neutropenia and mobilize PBPCs for their autologous and allogeneic transplantation. It shortens neutropenia and thus reduces the frequency of neutropenic fever. We compared the efficiency of glycosylated rHu and non-glycosylated Hu G-CSF in mobilizing hematop...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2009.150
更新日期：2010-02-01 00:00:00
abstract：:Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1705811
更新日期：2007-10-01 00:00:00
abstract：:YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor p...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2016.192
更新日期：2016-12-01 00:00:00
abstract：:The potent immunostimulatory cytokine interleukin-2 (IL-2) has been extensively investigated for its potential to induce anti-tumor immunity in a number of tumor models. Only recently the complex interplay of mutually suppressive or supportive cytokines of the IL-2-induced network of cytokines has been better characte...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章
doi：10.1038/sj.bmt.1702431
更新日期：2000-07-01 00:00:00
abstract：:A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：
更新日期：1996-07-01 00:00:00
abstract：:Intrabone marrow cord blood transplantation (IB-CBT) was proposed as a promising treatment modality to improve hematological recovery. However, clinical advantages of IB-CBT over conventional IV CBT have been unclear. We conducted a prospective single-center trial of IB-CBT to evaluate its safety and superiority in te...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/bmt.2016.319
更新日期：2017-04-01 00:00:00
abstract：:The effect of hematopoietic growth factors on neutrophil recovery after allogeneic transplantation is well-recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of GVHD is unclear. We perform...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,meta分析
doi：10.1038/sj.bmt.1704228
更新日期：2003-10-01 00:00:00
abstract：:Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not ...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702500
更新日期：2000-07-01 00:00:00
abstract：:G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34+ aPBPCT, we analyzed the ...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.bmt.1701795
更新日期：1999-06-01 00:00:00
abstract：:Availability of an HLA-identical sibling (MRD) or suitably matched unrelated donor (MUD) has historically been a limiting factor in the application of allogeneic hematopoietic transplantation. Although almost all patients have an HLA-haploidentical family donor, prior attempts at transplantation from such donors using...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/bmt.2014.62
更新日期：2014-08-01 00:00:00
abstract：:We describe two patients who developed respiratory syncytial virus (RSV) pneumonia after BMT. One died of RSV pneumonia after three courses of steroid pulse therapy. Surprisingly, RSV antigen was identified in the bronchoalveolar lavage fluid (BALF) obtained post mortem. Steroid pulse therapy might have suppressed ant...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702559
更新日期：2000-09-01 00:00:00
abstract：:We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.bmt.1704521
更新日期：2004-07-01 00:00:00
abstract：:Invasive fungal infections (IFI) with substantial mortality constitute an increasing problem among BMT patients. From 1986 to 1996 148 children underwent BMT, and are included in a retrospective analysis of the incidence, risk factors and outcome of IFI. By histopathology or culture-proven IFI (Candida, 10; Aspergillu...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1702654
更新日期：2000-11-01 00:00:00
abstract：:A potential link between arsenic (ATO)-based therapy and delayed hematopoietic recovery after autologous hematopoietic SCT (HSCT) for acute promyelocytic leukemia (APL) has previously been reported. We retrospectively reviewed the clinical histories of 58 patients undergoing autologous HSCT for APL at 21 institutions ...
journal_title：Bone marrow transplantation
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1038/bmt.2014.201
更新日期：2015-01-01 00:00:00
abstract：:One hundred and ninety-three patients with hematological malignancies and a follow-up > or =1 year, treated with stem cell transplantation (45 autologous, 99 allogeneic T cell-depleted matched, 49 allogeneic T cell-depleted mismatched) from July 1985 to May 1998, were considered evaluable for the development of catara...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：10.1038/sj.bmt.1703400
更新日期：2002-03-01 00:00:00
abstract：:To get an insight into the degree of major histocompatibility mismatches in donor/recipient (D/R) combinations who were 'ABDR-matched' by serology for class I and by oligotyping for DR1-14 (low resolution typing), we performed additional HLA testing using a combination of molecular, biochemical and cellular techniques...
journal_title：Bone marrow transplantation
pub_type： 杂志文章
doi：
更新日期：1995-11-01 00:00:00
abstract：:Whereas patients with multiple myeloma continue to relapse after autologous transplantation and are unlikely to be cured, the probability of progression is less after allogeneic transplantation and a proportion of patients may be cured. This is attributable to an immunologically mediated graft-versus-myeloma (GVM) eff...
journal_title：Bone marrow transplantation
pub_type： 杂志文章,评审
doi：10.1038/sj.bmt.1701459
更新日期：1998-11-01 00:00:00
